820236-81-5

Basic information

• Product Name: Methyl 2-bromo-6-fluorobenzoate
• Synonyms: Methyl 2-bromo-6-fluorobenzoate
• CAS NO: 820236-81-5
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 820236-81-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: Methyl 2-bromo-6-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-bromo-6-fluorobenzoate(820236-81-5)
• EPA Substance Registry System: Methyl 2-bromo-6-fluorobenzoate(820236-81-5)

Safety Data

• Hazardous Substances Data: 820236-81-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-bromo-6-fluorobenzoate is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structural features, including the presence of bromine and fluorine atoms, make it a valuable building block for the development of new drugs with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Agrochemical Industry:
Methyl 2-bromo-6-fluorobenzoate is also used as a precursor in the synthesis of agrochemicals, including pesticides and herbicides. Its chemical properties allow for the creation of compounds with targeted biological activity, contributing to the development of more effective and environmentally friendly agricultural products.
Used in Organic Synthesis:
Methyl 2-bromo-6-fluorobenzoate serves as a versatile reagent in organic synthesis, enabling the preparation of complex organic molecules with diverse applications. Its reactivity and functional groups make it suitable for various chemical reactions, such as nucleophilic substitution, electrophilic aromatic substitution, and cross-coupling reactions, facilitating the synthesis of a wide range of organic compounds.
Used in Medicinal Chemistry Research:
Methyl 2-bromo-6-fluorobenzoate is utilized in medicinal chemistry research for the design and synthesis of novel bioactive molecules. Its unique structural features and reactivity provide opportunities for the exploration of new chemical space and the discovery of potential drug candidates with novel mechanisms of action.
Safety Considerations:
It is important to handle Methyl 2-bromo-6-fluorobenzoate with care, as it may pose certain hazards if not used properly. Appropriate safety measures, such as wearing personal protective equipment, working in a well-ventilated area, and following proper disposal procedures, should be taken to minimize potential risks associated with its use.

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)7-5(9)3-2-4-6(7)10/h2-4H,1H3

Upstream product

• 851368-08-6 1-bromo-2-fluoro-6-iodobenzene 
• 2252-37-1 2-bromo-6-fluorobenzoic acid 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 1121-86-4 1-Fluoro-3-iodobenzene 
• 1073-06-9 3-fluorobromobenzene 
• 186581-53-3 diazomethane 

Downstream Products

• 1352133-13-1 methyl 2-cyclopropyl-6-fluorobenzoate 
• 1352133-14-2 (2-cyclopropyl-6-fluorophenyl)-methanol 
• 1352133-15-3 2-chloromethyl-1-cyclopropyl-3-fluorobenzene 
• 1352133-16-4 6-bromo-8-(2-cyclopropyl-6-fluoro-benzyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352133-17-5 6-bromo-8-(2-cyclopropyl-6-fluorobenzyl)-2-methanesulfinyl-8H-pyrido [2,3-d]pyrimidin-7-one 
• 1352133-18-6 6-bromo-8-(2-cyclopropyl-6-fluorobenzyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352132-86-5 8-(2-cyclopropyl-6-fluorobenzyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-6-prop-1-ynyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1352132-87-6 8-(2-cyclopropyl-6-fluorobenzyl)-6-ethynyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1256593-43-7 methyl 2-fluoro-6-formylbenzoate 

Relevant articles and documents

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

The YAP-TEAD transcriptional complex is responsible for the expression of genes that regulate cancer cell growth and proliferation. Dysregulation of the Hippo pathway due to overexpression of TEAD has been reported in a wide range of cancers. Inhibition of TEAD represses the expression of associated genes, demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization experiments confirmed that LM98 is anchored within the palmitic acid pocket of TEAD. LM98 reduces the expression of CTGF and Cyr61, inhibits MDA-MB-231 breast cancer cell migration and arrests cell cycling in the S phase during cell division.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR

The invention relates to the field of pharmaceutical chemistry. Specifically, the present invention relates to a series of BET (bromodomain and extra-terminal domain) inhibitors having a novel structure, particularly inhibitors targeting BRD4 (Bromodomain-containing protein 4), and a preparation method and use therefor. The structure thereof is shown in the following general formula (I). Said compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or crystal form thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical compsosition thereof can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Synthesis and structure-activity studies of the V-ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs

An efficient total synthesis of the potent V-ATPase inhibitor saliphenylhalamide (SaliPhe), a synthetic variant of the natural product salicylihalamide A (SaliA), has been accomplished aimed at facilitating the development of SaliPhe as an anticancer and antiviral agent. This new approach enabled facile access to derivatives for structure-activity relationship studies, leading to simplified analogs that maintain SaliPhe's biological properties. These studies will provide a solid foundation for the continued evaluation of SaliPhe and analogs as potential anticancer and antiviral agents.

PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

PAK INHIBITORS FOR THE TREATMENT OF CANCER

Provided herein are methods of utilizing PAK inhibitors for the treatment of cancer. Further provided herein are compounds and formulations utilized for the treatment of cancer.

6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.

Discovery of Potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists

The bradykinin B1 receptor is rapidly induced upon tissue injury and inflammation, stimulating the production of inflammatory mediators resulting in plasma extravasation, leukocyte trafficking, edema, and pain. We have previously reported on sulfonamide and sulfone-based B1 antagonists containing a privileged bicyclic amine moiety leading to potent series of 2-oxopiperazines. The suboptimal pharmacokinetics and physicochemical properties of the oxopiperazine sulfonamides led us to seek B1 antagonists with improved druglike properties. Using a pharmacophore model containing a bicyclic amine as anchor, we designed a series of amide antagonists with targeted physicochemical properties. This approach led to a novel series of potent phthalazinone B1 antagonists, where we successfully replaced a sulfonamide acceptor with a cyclic carbonyl unit. SAR studies revealed compounds with subnanomolar B1 binding affinity. These compounds demonstrate excellent cross-species PK properties with high oral bioavailability and potent activity in a rabbit biochemical challenge pharmacodynamic study.

Promoting or preventing haloaryllithium isomerizations: Differential basicities and solvent effects as the crucial variables

Deprotonation-triggered heavy halogen migrations should become a favorite tool in arene synthesis if their occurrence and outcome could be made predictable. Particularly attractive, though extremely rare, are stop-and-go situations where a first intermediate, generated by metalation, can be trapped at -100 °C, whereas at -75 °C halogen migration gives rise to an isomer. As shown now, one can conveniently produce the initial aryllithium species by halogen/metal interconversion in toluene at -100 °C, under conditions that preclude, halogen migration, and unleash the isomerization process by adding tetrahydrofuran at -75 °C.